113 related articles for article (PubMed ID: 26867804)
21. The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity.
Martinez-Velez N; Xipell E; Jauregui P; Zalacain M; Marrodan L; Zandueta C; Vera B; Urquiza L; Sierrasesúmaga L; Julián MS; Toledo G; Fueyo J; Gomez-Manzano C; Torre W; Lecanda F; Patiño-García A; Alonso MM
J Bone Miner Res; 2014 Oct; 29(10):2287-96. PubMed ID: 24737304
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
[TBL] [Abstract][Full Text] [Related]
23. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
24. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells.
Benassi MS; Chiechi A; Ponticelli F; Pazzaglia L; Gamberi G; Zanella L; Manara MC; Perego P; Ferrari S; Picci P
Cancer Lett; 2007 Jun; 250(2):194-205. PubMed ID: 17113707
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol.
Bacci G; Ferrari S; Longhi A; Forni C; Bertoni F; Fabbri N; Zavatta M; Versari M
J Chemother; 2001 Feb; 13(1):93-9. PubMed ID: 11233808
[TBL] [Abstract][Full Text] [Related]
26. Localized Co-delivery of Doxorubicin, Cisplatin, and Methotrexate by Thermosensitive Hydrogels for Enhanced Osteosarcoma Treatment.
Ma H; He C; Cheng Y; Yang Z; Zang J; Liu J; Chen X
ACS Appl Mater Interfaces; 2015 Dec; 7(49):27040-8. PubMed ID: 26575336
[TBL] [Abstract][Full Text] [Related]
27. MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells.
Wang B; Fang L; Zhao H; Xiang T; Wang D
Acta Biochim Biophys Sin (Shanghai); 2012 Aug; 44(8):685-91. PubMed ID: 22843172
[TBL] [Abstract][Full Text] [Related]
28. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
29. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
Pishas KI; Neuhaus SJ; Clayer MT; Schreiber AW; Lawrence DM; Perugini M; Whitfield RJ; Farshid G; Manavis J; Chryssidis S; Mayo BJ; Haycox RC; Ho K; Brown MP; D'Andrea RJ; Evdokiou A; Thomas DM; Desai J; Callen DF; Neilsen PM
Cancer Res; 2014 Feb; 74(3):921-31. PubMed ID: 24336067
[TBL] [Abstract][Full Text] [Related]
30. Nutlin-3 induces BCL2A1 expression by activating ELK1 through the mitochondrial p53-ROS-ERK1/2 pathway.
Lee SY; Choi HC; Choe YJ; Shin SJ; Lee SH; Kim HS
Int J Oncol; 2014 Aug; 45(2):675-82. PubMed ID: 24867259
[TBL] [Abstract][Full Text] [Related]
31. Biodegradable cisplatin polymer in limb-sparing surgery for canine osteosarcoma.
Withrow SJ; Liptak JM; Straw RC; Dernell WS; Jameson VJ; Powers BE; Johnson JL; Brekke JH; Douple EB
Ann Surg Oncol; 2004 Jul; 11(7):705-13. PubMed ID: 15231525
[TBL] [Abstract][Full Text] [Related]
32. Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells.
Sonnemann J; Palani CD; Wittig S; Becker S; Eichhorn F; Voigt A; Beck JF
Eur J Cancer; 2011 Jun; 47(9):1432-41. PubMed ID: 21334198
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
[TBL] [Abstract][Full Text] [Related]
34. Using targeted magnetic arsenic trioxide nanoparticles for osteosarcoma treatment.
Li XS; Li WQ; Wang WB
Cancer Biother Radiopharm; 2007 Dec; 22(6):772-8. PubMed ID: 18158768
[TBL] [Abstract][Full Text] [Related]
35. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
Müller CR; Paulsen EB; Noordhuis P; Pedeutour F; Saeter G; Myklebost O
Int J Cancer; 2007 Jul; 121(1):199-205. PubMed ID: 17354236
[TBL] [Abstract][Full Text] [Related]
36. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
Robson H; Meyer S; Shalet SM; Anderson E; Roberts S; Eden OB
Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
[TBL] [Abstract][Full Text] [Related]
37. The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40.
Secchiero P; Toffoli B; Melloni E; Agnoletto C; Monasta L; Zauli G
Acta Diabetol; 2013 Dec; 50(6):899-906. PubMed ID: 23615706
[TBL] [Abstract][Full Text] [Related]
38. Limb-sparing treatment for osteosarcoma in dogs.
LaRue SM; Withrow SJ; Powers BE; Wrigley RH; Gillette EL; Schwarz PD; Straw RC; Richter SL
J Am Vet Med Assoc; 1989 Dec; 195(12):1734-44. PubMed ID: 2599960
[TBL] [Abstract][Full Text] [Related]
39. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Michaelis M; Rothweiler F; Klassert D; von Deimling A; Weber K; Fehse B; Kammerer B; Doerr HW; Cinatl J
Cancer Res; 2009 Jan; 69(2):416-21. PubMed ID: 19147553
[TBL] [Abstract][Full Text] [Related]
40. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53.
Drakos E; Atsaves V; Schlette E; Li J; Papanastasi I; Rassidakis GZ; Medeiros LJ
Leukemia; 2009 Dec; 23(12):2290-9. PubMed ID: 19741726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
